Table 4 Baseline characteristics and renal outcomes (after rivaroxaban, apixaban, and edoxaban 2:2:1 propensity score matching)

N

208

208

104

Gender (male)

128 (61.5)

137 (65.9)

71 (68.3)

0.447

0.005

0.008

0.003

Mean age

70 ± 10.3

70 ± 10.0

69 ± 10.0

0.967

0.004

0.026

0.030

 Type 2 DM

49 (23.6)

49 (23.6)

23 (22.1)

0.953

0

0.003

0.003

 Hypertension

101 (48.6)

101 (48.6)

47 (45.2)

0.828

0

0.005

0.005

 Hyperlipidemia

57 (27.4)

57 (27.4)

34 (32.7)

0.565

0

0.010

0.010

 Heart failure

19 (9.1)

13 (6.3)

9 (8.7)

0.523

0.010

0.002

0.009

 Previous stroke

11 (5.3)

9 (4.3)

5 (4.8)

0.900

0.004

0.002

0.002

 Vascular disease

6 (2.9)

2 (1.0)

0 (0)

0.018

0.014

0.024

0.014

 Stage < 3

130 (62.5)

131 (63.0)

59 (56.7)

0.527

0.001

0.007

0.008

 Stage ≥3

78 (37.5)

77 (37.0)

45 (43.3)

0.001

0.009

0.010

 CHA2DS2-VASc

2.59 ± 1.34

2.52 ± 1.35

2.44 ± 1.40

0.652

0.052

0.109

0.058

 ACEI/ARB

131 (63.0)

112 (53.8)

69 (66.3)

0.055

0.012

0.004

0.016

 Spironolactone

0 (0)

1 (0.5)

1 (1.0)

0.160

0.010

0.014

0.006

 The average serum Cr (mg/dL)

1.08 ± 0.32

1.10 ± 0.35

1.13 ± 0.35

0.504

0.060

0.149

0.086

 Baseline eGFR (mL/min/1.73 m²)

70.04 ± 22.25

69.57 ± 22.49

68.55 ± 21.88

0.856

0.021

0.068

0.046

 1-year eGFR (mL/min/1.73 m²)

67.53 ± 22.23

67.02 ± 20.75

69.60 ± 23.43

0.608

0.024

0.091

0.117

2-year eGFR (mL/min/1.73 m²)

67.13 ± 22.39

66.87 ± 23.40

67.37 ± 22.69

0.983

0.011

0.011

0.022

 Acute kidney injury (%)

5 (2.4)

10 (4.8)

4 (3.8)

0.423

0.013

0.008

0.005

 Renal failure requiring HD (%)

1 (0.5)

0 (0)

0 (0)

0.400

0.010

0.010

–

 Renal death (%)

1 (0.5)

0 (0)

1 (1.0)

0.160

0.010

0.006

0.014